Pfizer gives up on studies of domagrozumab in DMD

In a disappointment for the company, Pfizer (NYSE: PFE) has scrapped the development of a potential Duchenne muscular dystrophy (DMD) candidate, a therapeutic area that the US pharma giant only entered in early 2015.

Pfizer yesterday announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of DMD: a Phase II safety and efficacy study (B5161002) and an open-label extension study (B5161004).

The Phase II study (B5161002), did not meet its primary efficacy endpoint, which was to demonstrate a difference in the mean change from baseline in 4 Stair Climb (in seconds) following one year of treatment with domagrozumab as compared to placebo in patients with DMD. Further evaluation of the totality of evidence including secondary endpoints did not support a significant treatment effect.